Mer­sana halves work­force in light of ovar­i­an can­cer tri­al flop, spelling end to its lead ADC

Mer­sana Ther­a­peu­tics will lay off about half its work­force and repri­or­i­tize af­ter a Phase III tri­al fail­ure in plat­inum-re­sis­tant ovar­i­an can­cer, send­ing shares $MRSN tank­ing …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER